|
Research Area
|
|
Description
|
Cancer |
|
Biological Activity
|
|
Description
|
SB 431542 is a potent and selective inhibitor of ALK5 with IC50 of 94 nM. |
|
Targets
|
ALK5 |
|
|
|
|
|
|
IC50 |
94 nM [1] |
|
|
|
|
|
|
In Vitro
|
SB 431542 inhibits the activin type I receptor ALK4 and the nodal type I receptor ALK7, which are responsible for the phosphorylation of Smad2. SB 431542 has little effect on ALK1, ALK2, ALK3, and ALK6, which show phosphorylation of Smad1. SB 431542 is a selective inhibitor of endogenous activin but has no apparent effect on BMP signaling. SB 431542 could induce both Smad2/Smad4- and Smad3/Smad4-dependent transcription. [2] In A498 cells, SB 431542 inhibits both TGF-β1–induced collagen Iα1 and PAI-1 mRNA with IC50 values of 60 and 50 nM, respectively. In addition, SB 431542 inhibits production of TGF-β1–induced fibronectin mRNA and protein with IC50 of 62 and 22 nM, respectively. [3] SB 431542 blocks the TGF-β–mediated growth factors, including PDGF-A, FGF-2 and HB-EGF, leading to an increase in proliferation of MG63 cells. SB 431542 also inhibits TGF-β–induced c-Myc and p21 WAF1/CIP1. [4] SB 431542 significantly suppresses TGF-β–induced G1 arrest, leading to accumulation of cells in the S phase of the cell cycle in FET, RIE, and Mv1Lu cells. SB 431542 also inhibits TGF-β-induced epithelial to mesenchymal transition (EMT) in NMuMG and PANC-1 cells. [5] SB 431542 significantly elevates the expression of CD86 in BM-DCs and that of CD83 within CD11c+ cells suppressed by TGF-β. SB 431542 is able to induce NK activity through functional maturation and IL-12 production of human DCs. [6] |
|
In Vivo
|
SB 431542 triggers cytotoxic T lymphocyte (CTL) activities in the colon-26 carcinoma models and is most likely to produce antitumor immunological outcomes through alteration of DC function suppressed by TGF-β. [6] |
|
Clinical Trials
|
|
|
Features
|
|
|
Protocol
|
|
Kinase Assay
[1]
|
| Flashplate assay for ALK5 |
SB 431542 is dissolved in DMSO at a concentration of 10 mM. The kinase domain of TGFβRI, from amino acid 200 to the C-terminus, and the full-length Smad3 protein are expressed as N-terminal glutathion S-transferase (GST) fusion proteins in the baculovirus expression system. Proteins are purified with glutathion Sepharose beads 4B. Basic FlashPlates are coated with 0.1 M sterile filtered sodium bicarbonate, pH 7.6, containing 700 ng of GST-Smad3 per 100 μL. Assay buffer contains 50 mM HEPES (pH 7.4), 5 mM MgCl2, 1 mM CaCl2, 1 mM DTT, 100 mM GTP, 3 μM ATP plus 0.5 μCi/well ?33P-ATP, and 85 ng of GST-ALK5 with or without SB 431542. Plates are incubated at 30 °C for 3 hours. The assay buffer is removed by aspiration, and the plate is counted on a Packard TopCount 96-well scintillation plate reader. |
|
Cell Assay
[4]
|
| Cell Lines |
MG63 and NIH3T3 |
| Concentrations |
0.3 μM |
| Incubation Time |
30 minutes |
| Methods |
To explore the effects of ligands, MG63 and NIH3T3 cells are seeded at a density of 8 × 104 cells/well in 6-well plates and starved (0.1% FCS for MG63 cells and 0.5% FCS for NIH3T3 cells) for 24 hours before ligand stimulation. Media containing various ligands are exchanged at 48-hours intervals. Cells are trypsinized and counted by a Coulter counter on days 2, 4, and 6 after ligand stimulation. To explore the effects of constitutively active receptors, cells are seeded at a density of 2 × 105 cells/well in 6-well plates. The next day, cells are infected with adenoviruses carrying various cDNAs at a multiplicity of infection of 100. Cells are trypsinized and counted on day 3. Cell proliferation assay is performed in the presence of 0.3 μM SB 431542. |
|
Animal Study
[6]
|
| Animal Models |
BALB/c mice receive intraperitoneal (i.p.) injections of colon-26 tumor cells. |
| Formulation |
DMSO |
| Doses |
1 μM solution, 100 μL/mouse |
| Administration |
Directly injected into peritoneal cavity |
|
References |
|
[1] Callahan JF, et al. J Med Chem, 2002, 45(5), 999-1001.
|
|
[2] Inman GJ, et al. Mol Pharmacol, 2002, 62(1), 65-74.
|
|
[3] Laping NJ, et al. Mol Pharmacol, 2002, 62(1), 58-64.
|
|
[4] Matsuyama S, et al. Cancer Res, 2003, 63(22), 7791-7798.
|
|
[5] Halder SK, et al. Neoplasia, 2005, 7(5), 509-521.
|
|
[6] Tanaka H, et al. Oncol Rep, 2010, 24(6), 1637-1643.
|
|